<DOC>
	<DOCNO>NCT00517595</DOCNO>
	<brief_summary>The primary objective determine progression free survival pemetrexed , gemcitabine plus bevacizumab first-line chemotherapy elderly patient Stage IIIB/IV non-small cell lung cancer ( NSCLC ) . The secondary objective determine overall response rate ; overall survival ; chemotherapy induce toxicity profile combination ; time progression ; patient report symptom burden .</brief_summary>
	<brief_title>Phase II Study Alimta Gemzar + Avastin First Line Chemotherapy Elderly Patients With Stage IIIB/IV NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patient provide voluntary write informed consent performance studyrelated procedure part normal medical care . Patient ≥ 65 year age ECOG 0 1 Patient must histologically/cytologically confirm Stage IIIB/IV NSCLC . Patient measurable disease define least 1 lesion accurately measure least 1 dimension ( CT MRI ) &amp; use ass response define RECIST criterion . Tumors within previously irradiate field designate nontarget lesion . Patient receive radiotherapy within 2 week ( 4 week require brain metastasis radiotherapy ) initial chemotherapy dosing study , acute toxicity due prior radiotherapy resolve prior initial chemotherapy dosing . Patient negative serum pregnancy test undergone hysterectomy time enrollment . Greater 12 week life expectancy . Patient recover recent surgery least 30 day &amp; free active infection require antibiotic . Patient must willing/able discontinue use NSAIDS prior study drug dosing . Patient must able take folic acid , Vitamin B12 , &amp; dexamethasone per protocol . Patient must exhibit great Grade 1 peripheral neuropathy . Prior systemic concurrent chemo metastatic NSCLC ( Prior Tarceva allow ) .Prior adjuvant chemo acceptable long &gt; 12 month since completion prior pemetrexed , gemcitabine bevacizumab . Lung carcinoma squamous cell histology ( mixed tumor categorize predominant cell type unless small cell element present , case patient ineligible ; sputum cytology alone acceptable.Patients extrathoraciconly squamous cell NSCLC eligible.Patients peripheral lung lesion ( NSCLC histology ) also eligible ( peripheral lesion define lesion epicenter tumor ≤ 2 cm costal diaphragmatic pleura threedimensional orientation base lobe lung &gt; 2 cm trachea , main , lobar bronchus ) . Hemoptysis within 1 month prior study enrollment Ongoing treatment fulldose warfarin equivalent i.e. , unfractionated and/or low molecular weight heparin . ( Low dose warfarin 1 mg give prophylaxis allow ) . Hypersensitivity component Alimta , gemcitabine &amp; /or bevacizumab , &amp; /or tolerate folic acid , corticosteroid Vitamin B12 supplement . Currently/have recently take longacting NSAID ( Ibuprofen ≤ 400 mg QID acceptable ) aspirin ( &gt; 325mg/day ) within 5 day initial pemetrexed administration . Clinically significant pericardial/pleural effusion ascites unless able drain study entry . Presence third space fluid control drainage . Core biopsy/other minor surgical procedure ( exclude placement vascular access device ) within 7 day prior study enrollment . Active infection fever ≥ 38.5°C within 3 day first schedule day protocol treatment . Serious , nonhealing wound , ulcer , untreated bone fracture . NYHA Grade II great CHF Inadequately control hypertension ( define systolic blood pressure &gt; 150 &amp; /or diastolic blood pressure &gt; 100mmHg antihypertensive med ) Any prior history hypertensive crisis hypertensive encephalopathy . History MI , CVA , TIA , unstable angina within 6 month study enrollment . Significant vascular disease ( aortic aneurysm , aortic dissection recent peripheral arterial thrombosis . ) Symptomatic peripheral vascular disease Known bleeding diathesis coagulopathy Presence CNS ( central nervous system ) except treat brain metastasis . Treated brain metastasis define evidence progression hemorrhage treatment ongoing requirement dexamethasone , ascertain clinical examination brain imaging ( MRI CT ) screen period.Anticonvulsants ( stable dose ) allowed.Treatment brain metastasis may include whole brain radiotherapy ( WBRT ) , radiosurgery ( RS ; Gamma Knife , LINAC , equivalent ) combination deem appropriate treating physician.Radiotherapy must complete least 4 week prior study enrollment acute radiotherapy toxicity resolved.Patients CNS metastasis treat neurosurgical resection brain biopsy perform within 3 month prior Day 1 exclude . A major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 anticipation need major surgical procedure course study . Abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior enrollment . History prior malignancy within past 5 year except curatively treat basal cell carcinoma skin , cervical intraepithelial neoplasia , localized prostate cancer current prostate specific antigen &lt; 1.0 mg/dL 2 successive evaluation , least 3 month apart , recent evaluation 4 week prior entry . Have receive radiotherapy 25 % bone marrow . Receiving concurrent investigational therapy receive investigational therapy within 30 day first schedule day protocol treatment Pregnant/lactating . Any medical condition deem Investigator likely interfere patient 's ability sign inform consent , cooperate/participate study , interfere interpretation result . History allogeneic transplant . Known HIV infection Hepatitis B C .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>